On point Hulk. I'm only 3 years in, and I still believe we have a lot of potential. However, my eyes are wide open as to the risks of the competitive marketplace and the difficulty in getting approved to actually sell the drug. We had just hit our PE on the HIV combo P3 trial when I invested, and I wouldn't have believed you if you said it would take 4 more years to get the drug on the market. At the same time, the new indications have added all the more potential, but it's just potential until we prove our worth.

COVID was both positive and negative. The positive is we put a lot of new eyes on the company, but we have made zero progress on HIV (actually backed up), and very little on cancer, et al. Pre-Covid, we were around $1.20, so we had some fun days with the stock price, and money was easier to obtain. However, that's no longer the case as we sit here today.

We're still roughly double the share price, but we are no closer to getting the HIV BLA done than we were a year ago, but that RTF throws up more red flags than I was seeing a year ago. Further, competitive products are being advanced. I'm like you in that I just don't believe that we'll have a catalyst very near term that pushes us out of the $2's without a revenue generator. The number of shareholders should keep us from falling all the way back, but it's back to a long game after watching for a bomb every day while COVID was playing out. The people who don't like that statement are largely the same ones who were saying $20 in Feb and $50 by June.